Pacira Pharmaceuticals
12
11M
7
0.35
3
0.42
1
- Areas of investment
Summary
Pacira Pharmaceuticals is the famous Corporate Investor, which was founded in 1989. The main department of described Corporate Investor is located in the San Diego. The venture was found in North America in United States.
The increased amount of exits for fund were in 2019. The important activity for fund was in 2017. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year.
The typical case for the fund is to invest in rounds with 4 participants. The meaningful sponsors for the fund in investment in the same round are Signet Healthcare Partners, Quaker Partners, OrbiMed. In the next rounds fund is usually obtained by ProMedica Health System, Checkmate Capital.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Life Science. Among the various public portfolio startups of the fund, we may underline TELA Bio For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Investments analytics
Analytics
- Total investments
- 12
- Lead investments
- 3
- Exits
- 1
- Rounds per year
- 0.35
- Follow on index
- 0.42
- Investments by industry
- Biotechnology (11)
- Pharmaceutical (6)
- Medical (5)
- Health Care (4)
- Biopharma (3) Show 5 more
- Investments by region
-
- United States (8)
- Germany (3)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 0.58
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Spine BioPharma | 28 Mar 2022 | Biotechnology, Medical, Pharmaceutical | Early Stage Venture | 13M | United States, New York, New York |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.